Dr. Jacques Mallet, voormalig SVP van Portfolio Analytics/Corporate Strategy bij Sanofi, treedt toe tot de adviesraad van NEUWAY als onafhankelijk lid en voegt diepgaande expertise toe op het gebied van bedrijfsontwikkeling, financiering en klinische zaken in de farmaceutische sector

BONN, Duitsland–(BUSINESS WIRE)– NEUWAY Pharma GmbH, « NEUWAY », een preklinisch biotechnologiebedrijf dat gespecialiseerd is in de levering van innovatieve biotherapeutische geneesmiddelen via zijn gepatenteerde EnPC®-medicijnafgifte technologie, kondigde vandaag de benoeming aan van Dr. Jacques Mallet als een aanvullend onafhankelijk lid van de Raad van Advies.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20220909005184/en/

NEUWAY Pharma Appoints Healthcare Sector Veteran Dr Jacques Mallet to its Advisory Board

Dr Jacques Mallet, former SVP of Portfolio Analytics/Corporate Strategy at Sanofi, joins NEUWAY’s Advisory Board as independent member adding in depth expertise in pharma corporate development, financing and clinical affairs

BONN, Germany–(BUSINESS WIRE)– NEUWAY Pharma GmbH, « NEUWAY », a preclinical-stage biotechnology company specializing in the delivery of innovative biotherapeutic drugs through its proprietary EnPC® drug-delivery technology, announced today the appointment of Dr Jacques Mallet as an additional independent member of the Advisory Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005184/en/

Dr. Jacques Mallet (Photo: Business Wire)

Jacques Mallet, MD, previously served as SVP of Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed and private companies in the biotech and medtech sector.

“I’m delighted to join the Advisory Board to support NEUWAY in the development and growth of the company”, said Dr Mallet. “I have been impressed by the great capabilities of the EnPC® drug-delivery technology and its therapeutic applications, which offers many advantages for drug developers and patients.”

Dr Mallet brings more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy to NEUWAY, along with unique insights gained as a life-science venture capitalist in both in Europe and the United States. In addition to being responsible for investments at Auriga Partners, a French private-equity firm specializing in life sciences, Dr Mallet has also held executive positions in global consulting firms including Monitor Deloitte and Accenture.

Welcoming Dr Mallet, NEUWAY’s Advisory Board Chairman and General Partner at Wellington Partners, Dr Rainer Strohmenger, said, “We are proud to have attracted such a distinguished expert to join the board of NEUWAY. Dr Mallet’s experience in clinical research and portfolio management, makes him an excellent fit for NEUWAY.”

Dr Oliver Ernst, Chief Executive Officer of NEUWAY, added, “I am delighted to welcome Dr Mallet to our Board. With his extensive experience Dr Mallet will greatly support our corporate and product development efforts towards partnerships and the first clinical applications of our unique EnPC® drug-delivery technology.”

About NEUWAY Pharma

NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).

Learn more at www.neuway-pharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005184/en/

Contacts

NEUWAY Pharma Contact:

Christine Kuhn
+49 228-522198-0
kuhn@neuway-pharma.com